PCAS, a specialist in complex molecules for the life sciences and technology sectors, announced on Wednesday evening that Seqens, its majority shareholder, plans to launch a tender offer for the 23.3% of the capital it does not yet hold.

The pharmaceutical synthesis giant, which already holds 77.7% of the capital, intends to offer eight euros per PCAS share, representing a premium of 7.4% over the last closing price prior to the announcement of the offer, i.e. 7.45 euros.

PCAS adds that Seqens intends to carry out a capital increase of around 200 million euros at the end of its simplified tender offer, in order to reduce the company's indebtedness and strengthen its shareholders' equity.

These announcements come at a time when PCAS has announced that it has returned to profit in the first six months of the year, with operating income of 36.4 million euros, compared with a loss of 30 million euros a year earlier.

Net income came to 25.4 million euros in the first half, compared with a loss of 32.2 million euros in the first half of 2022.

PCAS shares were suspended from trading on Euronext Paris on Thursday, a decision effective yesterday until further notice.

Copyright (c) 2023 CercleFinance.com. All rights reserved.